SCI Abstract

search
+
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial
Sovateltide (Tycamzzi™), an endothelin-B (ET-B) receptor agonist, increases cerebral blood flow, has anti-apoptotic ...
Fulzerasib: First Approval
Fulzerasib: First Approval
Fulzerasib (Dupert®; Innovent Biologics/GenFleet Therapeutics) is an orally active small molecule inhibitor of the KR...
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?
Highly variable pain mechanisms in people with low back pain or spine-related leg pain might contribute to inefficacy of n...
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
The accelerated approval (AA) pathway was established by the United States Food and Drug Administration (FDA) to provide e...
The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review
The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review
Gram-negative multidrug-resistant (MDR) bacteria, including Enterobacterales, Acinetobacter baumannii, and Pseudomonas aer...
Difficult-to-Treat Axial Spondyloarthritis: A New Challenge
Difficult-to-Treat Axial Spondyloarthritis: A New Challenge
Axial spondyloarthritis is a common form of chronic inflammatory rheumatic disease in adults, the treatment of which is ba...
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors ...
Odronextamab: First Approval
Odronextamab: First Approval
Odronextamab (Ordspono™), a CD20xCD3 bispecific antibody, is being developed by Regeneron Pharmaceuticals for the tr...
Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review
Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review
Trientine tetrahydrochloride (TETA-4HCl, Cuvrior®) is a copper chelating agent with the active moiety triethylenetetr...
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology
Due to the lack of a comprehensive pharmacology test set, evaluating the potential and value of large language models (LLM...
Xeligekimab: First Approval
Xeligekimab: First Approval
Xeligekimab (Jinlixi®) is a recombinant human interleukin (IL)-17A-neutralizing immunoglobulin (Ig)G4 monoclonal anti...
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials
The prescribing of opioids to patients for postoperative pain can lead to persistent opioid use. This review investigated ...
Gepirone Extended-Release: First Approval
Gepirone Extended-Release: First Approval
Gepirone HCL extended-release (gepirone ER; EXXUA™), an oral, selective serotonin (5HT)1A receptor agonist formulate...
New Therapies on the Horizon for Primary Biliary Cholangitis
New Therapies on the Horizon for Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failur...
Zilucoplan: First Approval
Zilucoplan: First Approval
Zilucoplan (Zilbrysq®) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 i...
Vamorolone: First Approval
Vamorolone: First Approval
Vamorolone (AGAMREE®) is an oral, selective, dissociative corticosteroid developed by ReveraGen BioPharma and Santher...
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis
Temporomandibular disorders (TMD) comprise a cluster of conditions with a wide range of etiological factors that causes pa...
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Funding The original article was supported by funding from Chung Sh...
Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”
Conflict of interest TWC and C-HH declare that they have no competi...
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated oncogenes in cancer and the mutationa...
Narlumosbart: First Approval
Narlumosbart: First Approval
Narlumosbart (津立生) is a recombinant, fully human, anti-receptor activator of nuclear factor kappa- ...
Spesolimab for the Treatment of Generalized Pustular Psoriasis
Spesolimab for the Treatment of Generalized Pustular Psoriasis
Generalized pustular psoriasis (GPP) is a rare but severe skin inflammatory disorder characterized by the eruption of wide...
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity h...
Correction to: Motixafortide: First Approval
Correction to: Motixafortide: First Approval
In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth s...
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
A randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intrao...
Nedosiran: First Approval
Nedosiran: First Approval
Nedosiran (RIVFLOZA™), a once-monthly subcutaneous small interfering RNA (siRNA) therapy, is being developed by Dice...
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage
With the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for tr...
Iruplinalkib: First Approval
Iruplinalkib: First Approval
Iruplinalkib (Trade name: 启欣可®; Code name: WX-0593), a highly selective oral anaplastic lymphoma...
Momelotinib: First Approval
Momelotinib: First Approval
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that ha...
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
Mitapivat (Pyrukynd®), an oral, allosteric activator of pyruvate kinase (PK), is approved in the USA for the treatmen...
Load More
format_indent_increase